The MRCF is a unique collaboration between CSL, major Australian superannuation funds, the Australian and New Zealand governments, Australian state governments and over 50 leading medical research institutes and research hospitals.
The MRCF supports the development and commercialisation of early-stage biomedical discoveries associated with member research organisations, providing both capital and expertise to guide the successful development of new therapies.
50+ Medical research institutes and hospitals
ACT Government
Queensland Government
Victorian Government
NSW Government Health
Ministry of Business, Innovation & Employment NZ
Brandon Capital
Australian Government
Australian Super
Hesta
Host Plus
Statewide Super
TelstraSuper
CSL
The University of Queensland Diamantina Institute (UQDI) is a modern research facility where clinical and basic science converge in the translational research of cancer, immunology and genomic medicine. The Institute is host to over 300 researchers, students and support staff. It lays claim to global, world-changing discoveries such as the world’s first cervical cancer vaccine.
ViewThe Burnet Institute is an independent, not‐for‐profit Australian organization that is unique in its approach of linking medical research with public health action to address many of the major health problems affecting disadvantaged communities. This approach allows us to develop innovative health solutions ranging from the highly technological through to those that are community-based.
View
Brandon Capital Partners Pty Ltd manages the MRCF Collaboration, providing seed and venture capital investment to support the development and international growth of Australian and New Zealand life science companies.
Learn more about the Brandon Capital Team
Through the internship it was fantastic to understand what Brandon are looking for in the projects they fund. The learnings from the internship program will be applied to the new projects we develop, both in reviewing the opportunity and developing a solid business plan that will increase the commercial success.
The internship was a valuable experience that filled a critical gap in my knowledge of how early-stage life science technologies are commercialised. Up to this point, my experience was from a technology development perspective, and I did not have a full understanding of what investors were seeking in potential investments. The internship experience is immeasurable and will pay dividends well into the future.
The internship was an excellent learning and development opportunity. I greatly improved my understanding of the venture capital financing model and elements such as valuation, due diligence, market analysis and drug development. The MRCF internship program also enabled me to expand my national commercialisation networks and work alongside experienced biotech investors.
